Literature DB >> 32495859

PKMYT1 aggravates the progression of ovarian cancer by targeting SIRT3.

Z-H Xuan1, H-P Wang, X-N Zhang, Z-X Chen, H-Y Zhang, M-M Gu.   

Abstract

OBJECTIVE: This experiment aims to elucidate the role of PKMYT1 in the malignant progression of ovarian cancer (OC) and its underlying mechanism. PATIENTS AND METHODS: Expression pattern of PKMYT1 in 43 paired OC tissues and adjacent normal ones was determined by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The potential relationship between PKMYT1 level and clinical data of OC patients was analyzed. PKMYT1 level in OC patients either with distant metastasis or not was examined. Through Cell Counting Kit (CCK-8) and transwell assay, influences of PKMYT1 on proliferative and metastatic abilities in 3AO and CAOV3 cells were assessed. At last, the role of PKMYT1/SIRT3 regulatory loop in the progression of OC was identified.
RESULTS: PKMYT1 was upregulated in OC tissues relative to controls. OC patients accompanied with distant metastasis had higher abundance of PKMYT1. High level of PKMYT1 predicted worse prognosis in OC patients. Knockdown of PKMYT1 attenuated proliferative, migratory, and invasive abilities in OC cells. Moreover, SIRT3 was downregulated in OC tissues, which was negatively correlated to PKMYT1. Silencing of SIRT3 could abolish the regulatory effect of PKMYT1 on proliferative and metastatic abilities in OC.
CONCLUSIONS: Upregulated PKMYT1 in OC is closely linked to distant metastasis and poor prognosis. PKMYT1 accelerates the malignant progression of OC via negatively regulating SIRT3.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32495859     DOI: 10.26355/eurrev_202005_21308

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

Review 1.  The Role and Therapeutic Perspectives of Sirtuin 3 in Cancer Metabolism Reprogramming, Metastasis, and Chemoresistance.

Authors:  QingYi Zhao; Jing Zhou; Feng Li; Sen Guo; Liang Zhang; Jing Li; Qin Qi; Yin Shi
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

2.  The DNA damage repair-related gene PKMYT1 is a potential biomarker in various malignancies.

Authors:  Changjian Shao; Yuanyong Wang; Minghong Pan; Kai Guo; Tamas F Molnar; Florian Kocher; Andreas Seeber; Martin P Barr; Alfons Navarro; Jing Han; Zhiqiang Ma; Xiaolong Yan
Journal:  Transl Lung Cancer Res       Date:  2021-12

3.  c-Myb-mediated inhibition of miR-601 in facilitating malignance of osteosarcoma via augmentation of PKMYT1.

Authors:  Peng Luo; Jiarui Fang; Houqing Chen; Feng He; Siying Xiao; He Liu; Shizhuang Zhu; Jianzhou Luo; Changqing Jiang
Journal:  Sci Rep       Date:  2022-04-23       Impact factor: 4.996

4.  Overexpression of PKMYT1 Facilitates Tumor Development and Is Correlated with Poor Prognosis in Clear Cell Renal Cell Carcinoma.

Authors:  Peng Chen; Ziying Zhang; Xiang Chen
Journal:  Med Sci Monit       Date:  2020-10-07

5.  PKMYT1 regulates the proliferation and epithelial-mesenchymal transition of oral squamous cell carcinoma cells by targeting CCNA2.

Authors:  Ye Cai; Weidong Yang
Journal:  Oncol Lett       Date:  2021-12-27       Impact factor: 2.967

6.  Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification.

Authors:  Yiyang Hu; Chunli Gong; Zhibin Li; Jiao Liu; Yang Chen; Yu Huang; Qiang Luo; Sumin Wang; Yu Hou; Shiming Yang; Yufeng Xiao
Journal:  Mol Cancer       Date:  2022-02-03       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.